As Drug Prices Soar, Value-Based Pay Hits Pharmaceutical Industry
More health insurance companies are deciding to pay for a drug based on whether its effective and provides the patient a good outcome as value-based care inches toward the pharmaceutical industry, insurers and a new analysis indicate.
One in four health plans now have “at least one outcomes-based contract” with a drug maker , an Avalere Health survey showed. Such contracts tie health outcomes to whether the drug is paid for by the health plan.
One in four health plans now have “at least one outcomes-based contract” with a drug maker , an Avalere Health survey showed. Such contracts tie health outcomes to whether the drug is paid for by the health plan.